STOCK TITAN

Horizon Therapeutics Plc - HZNP STOCK NEWS

Welcome to our dedicated news page for Horizon Therapeutics Plc (Ticker: HZNP), a resource for investors and traders seeking the latest updates and insights on Horizon Therapeutics Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Horizon Therapeutics Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Horizon Therapeutics Plc's position in the market.

Rhea-AI Summary
Horizon Therapeutics acquired by Pillartree Limited, a wholly owned subsidiary of Amgen Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Horizon Therapeutics announces court sanctioning of scheme of arrangement for acquisition by Pillartree Limited
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
none
-
Rhea-AI Summary
Horizon Therapeutics plc (NASDAQ: HZNP) receives disclosure regarding dealings with relevant securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
none
-
Rhea-AI Summary
Michael Grey discloses interests in Horizon Therapeutics plc with 0.086% ownership of ordinary shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Horizon Therapeutics plc presents new data on TEPEZZA treatment regimen and impact of TED on QOL at ATA 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Jeff Himawan discloses ownership of 0.061% of Horizon Therapeutics plc's ordinary shares. No other relevant disclosures made.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
none
-
Rhea-AI Summary
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.04%
Tags
none
-
Rhea-AI Summary
Q32 Bio and Horizon Therapeutics have initiated a Phase 2 study to evaluate bempikibart in adult patients with severe alopecia areata, a common autoimmune disorder characterized by hair loss. The study aims to address the significant unmet medical need in this population. Bempikibart, a fully human anti-IL-7Rα antibody, has the potential to provide long-term improvement in hair loss. This development showcases the potential of bempikibart in treating autoimmune and inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
Rhea-AI Summary
Horizon confirms its issued ordinary share capital and outstanding options as of September 5, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
none
Horizon Therapeutics Plc

Nasdaq:HZNP

HZNP Rankings

HZNP Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About HZNP

at horizon therapeutics, we believe science and compassion must work together to transform lives. we are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. for us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.